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Summary. von Willebrand factor (VWF) plays key roles
in both primary and secondary hemostasis by capturing
platelets and chaperoning clotting factor VIII, respec-
tively. It is stored within the Weibel–Palade bodies
(WPBs) of endothelial cells as a highly prothrombotic
protein, and its release is thus necessarily under tight con-
trol. Regulating the secretion of VWF involves multiple
layers of cellular machinery that act together at different
stages, leading to the exocytic fusion of WPBs with the
plasma membrane and the consequent release of VWF.
This review aims to provide a snapshot of the current
understanding of those components, in particular the
members of the Rab family, acting in the increasingly
complex story of VWF secretion.
Keywords: endothelial cells, exocytosis, hemostasis, Rab
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Introduction
Endothelial von Willebrand factor (VWF) is well under-
stood to play a key role in hemostasis, acting directly to
recruit platelets to sites of vascular damage, and indirectly
by chaperoning clotting factor VIII to reduce its degrada-
tion and clearance. For VWF to be effective, it must be
secreted in a timely manner, at sufficient levels, and in an
appropriate structural format. These all rely on the proper
functioning of its carrier organelles, Weibel–Palade bodies
(WPBs). WPBs provide an environment in which the multi-
merization and folding of VWF can occur, they control the
quantum of VWF release via their size, and they are
actively involved in delivering VWF into the plasma. The
secretion of VWF is thus a complex process orchestrated
by intraorganellar events on the one hand, and cytoplasmic
machinery on the other.
WPBs were first seen by Ewald Weibel [1], then work-
ing with George Palade at Rockefeller University in New
York on St Valentine’s day 1962, and their initial charac-
terization during the early years has recently been well
described by their discoverer [2,3]. Their remarkable
shape might have made them a prime target for cell biol-
ogists, but, in fact, our understanding of these organelles
has lagged behind that of other, much less morphologi-
cally striking, anterograde carriers, such as chromaffin or
insulin granules. Recently, reviews of their structure and
function have become more frequent as interest in their
unique properties has increased [4–6]. Furthermore, the
number of other components associated with WPBs is
increasing in parallel with additional studies [7] (and ref-
erences therein). A brief overview of WPB formation and
function will be provided here for background, but this
review will focus on the most recently active areas of
research, in particular the machinery of exocytosis, the
modulation of exocytosis, and the roles of Rabs and their
effectors in these events. A schematic of the role of Rabs
in VWF secretion is shown in Fig. 1, and summaries of
the known WPB Rabs and their effectors are shown in
Tables 1 and 2, respectively.
Overview of VWF secretion
Two parallel interdependent activities underpin the release
of VWF. One is the biosynthesis of the remarkable struc-
ture that is the mature VWF protein assembly; multimer-
ized, coiled, and ready to be released. The other is the
formation and maturation of a cigar-shaped carrier,
which is enormous by comparison with other secretory
organelles. Without VWF, WPBs cannot form. Without
the specialized carrier, VWF cannot attain its functionally
active structure.
Biosynthesis of VWF
The VWF gene encodes a 2813 amino acid protein with
a 22 amino acid signal peptide and a 741 amino acid
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propeptide. Initially forming a dimer within the endoplas-
mic reticulum via C-terminal disulfide bonds, it travels
along the anterograde pathway into the Golgi apparatus,
where interchain disulfide bonds are formed, the propep-
tide is cleaved, and the remodeling of the multimerizing
protein into a proteinacious tubule commences. VWF is
incorporated into an immature carrier at the trans-Golgi
network (TGN), where the earliest-forming VWF tubules
can be seen by electron microscopy (EM) [8]. The imma-
ture WPB then carries the VWF towards the cell periph-
ery, and, during its subsequent maturation, the VWF
continues multimerizing and forming tubules [9]. At
exocytosis, very high molecular weight VWF is released
as long platelet-catching strings [10,11] that are par-
ticularly effective in primary hemostasis. Our rapidly
improving understanding of the structural aspects of mul-
timerization and tubulation has been recently reviewed
elsewhere [4,12].
Formation of WPBs
The formation of WPBs at the TGN has been evident
from the earliest EM investigations, even before it was
realized that the tubular content used as a marker of that
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Fig. 1. Formation and function of Weibel–Palade bodies (WPBs): focus on Rabs and their effectors. (1) The biogenesis of WPBs begins at the
trans-Golgi network, where tubules of von Willebrand factor (VWF) are inserted into the nascent storage organelle. This process is dependent
on the presence of a clathrin coat and the adaptor protein AP-1. Inhibition of either of these proteins results in a failure to form WPBs and
constitutive secretion of VWF (normally negligible). AP-1 also recruits the tripartite complex of aftipilin, p200, and c-synergin, which is
required (presumably by the recruitment of as yet unknown proteins) for the regulated release of VWF. Rab10 is also required for the rapid
regulated release of at least some VWF by a currently unknown mechanism. (2) Immature WPBs are trafficked by an as yet uncharacterized ki-
nesin(s) to the periphery of the cell along microtubules. (3) Immature WPBs can become anchored on F-actin by a tripartite complex consisting
of Rab27a, myosin and Rab27a-interacting protein (MyRIP), and myosin Va (MyoVa), and this allows peripheral localization and maturation
(further multimerization of VWF, condensation of tubules, and an increase in WPB length) of the WPBs for later regulated release; alterna-
tively, the immature WPBs are released basally at the cell surface, resulting in relatively short strings of VWF. WPBs also recruit Rab3B/
Rab3D and the Rab27a/Rab3 effector Slp4a (granuphilin), as well as Rab15 and the Rab27a/Rab15 effector Munc13-4. (4) Following secreta-
gogue stimulation, anchoring on actin is lost, and a Rab27a-dependent, Rab15-dependent and Munc13-4-dependent step at the cell surface is
required for exocytosis to occur (potentially via an interaction with Doc2a). (5) A Rab27a-dependent and Slp4a-dependent docking step is nec-
essary for release (potentially via an interaction with syntaxin or Munc18-1/Munc18-2). (6) VWF is released as high molecular weight strings at
the cell surface in a manner that is expedited by the contraction of a ring of actin.
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biogenesis reflected the presence of VWF [13]. This initial
formation is driven by the tubulation of VWF, as heterol-
ogous expression of VWF in certain other cell types
drives cigar-shaped WPB formation [14], and clear distor-
tion of the surrounding membrane accompanies even ini-
tial VWF tubulation [8]. Interestingly, a cytoplasmic
supporting structure is also required; a clathrin coat is
clearly present on the cytoplasmic face of forming WPBs
[15].
In the absence of the heterotetrameric clathrin adaptor
AP-1, a failure to recruit clathrin leads to the formation
of small VWF-containing carriers that are not capable of
supporting tubulation of VWF, and that do not respond
to secretagogue [15]. AP-1 also plays a more active role
in the formation of functional WPBs, because, in addition
to recruitment of the structural protein clathrin, it also
recruits the trimeric complex of p200, aftiphilin, and c-
synergin, a poorly understood complex that is essential
for the targeting of WPBs into the regulated secretory
pathway [16]. In their absence, AP-1 can still recruit
clathrin, and VWF is still organized into WPBs of identi-
cal morphology to controls, but there is a loss of regu-
lated secretion and a concomitant rise in basal secretion
(see below). The exact mechanism of aftiphilin–p200–c-
synergin action is enigmatic, but the localization of this
complex on immature perinuclear WPBs suggests the
early recruitment of a factor required for regulated release
or (less likely) of an inhibitor that blocks basal release.
AP-1 therefore coordinates the targeting and formation
of WPBs. In the absence of controlled delivery to the
blood (aftiphilin–c-synergin-dependent), formation of the
most highly prothrombotic forms of VWF (clathrin-
dependent) is also prevented. Thus, the most highly pro-
thrombotic forms of VWF cannot be made unless the
secretion of those organelles is regulated. Coupling of the
two processes via their mutual dependence on AP-1 thus
provides a useful checkpoint (Fig. 1).
After becoming independent of the TGN, WPBs are
redistributed via interactions with both microtubules (via
dynein and an as yet undefined kinesin[s]) and actin fila-
ments (via myosin Va [MyoVa]) in such a way as to shift
the overall distribution of the cell WPB population to the
periphery [17–20]. In parallel, recruitment of further com-
ponents, including the integral membrane protein CD63
[21,22] and the Rabs that play a major role in WPB func-
tioning (see below), occurs, as well as some remodeling of
Table 1 Rab proteins recruited to Weibel–Palade bodies (WPBs)
Rab Determination on WPBs Method
siRNA effect on
VWF release Comment Reference
Rab27a Endogenous expression and
overexpression
Western blot, RT-
PCR, and IF
Increase or decrease – [26,34,47,50]
Rab27b Overexpression RT-PCR Decrease Level of expression very low [47]
Rab3A Overexpression RT-PCR Decrease – [47]
Rab3B Endogenous expression and
overexpression
Western blot, RT-
PCR, and IF
No effect – [47,50]
Rab3D Endogenous expression and
overexpression
Western blot, RT-
PCR, and IF
Decrease or no
effect
Endogenous Rab3D weakly
detectable in 5% of cells
[47,50,52]
Rab15 Overexpression RT-PCR Decrease – [47]
Rab33a Overexpression RT-PCR No effect – [47]
Rab37 Overexpression RT-PCR No effect Low expression (cycle time 39.74) [47]
IF, Immunofluorescence microscopy; siRNA, small interfering RNA; VWF, von Willebrand factor.
Table 2 Rab effector proteins recruited to Weibel–Palade bodies (WPBs)
Rab effector
Determination on
WPB Method
siRNA effect
on VWF
release Comment Reference
MyRIP
(Slac2c)
Endogenous
expression and
overexpression
Western blot,
RT-PCR,
and IF
Increase Binds Rab27a* and MyoVa*/MyoVIIa [19,26,33,50,80]
Slp4a
(granuphilin)
Endogenous
expression and
overexpression
Western blot,
RT-PCR,
and IF
Decrease Binds Rab27a* (GTP-bound and GDP-bound), Rab3A-
D*, Rab8, syntaxin 1a, syntaxin 2, syntaxin 3,
Munc18-1, and Munc18-2
[50,55,56,81]
Munc13-4 Overexpression Western blot Decrease Binds Rab27a/b*, Rab15*, and Doc2a. [47,82,83]
MyoVa Endogenous
expression and
overexpression
Western blot,
RT-PCR,
and IF
Decrease Binds MyRIP*, Slp4a, Rab8, Rab3, Rab10, and
melanophilin
[19,59,84–86]
IF, Immunofluorescence microscopy; MyoVa, myosin Va; MyoVIIa, myosin VIIa; MyRIP, myosin and Rab27a-interacting protein; siRNA,
small interfering RNA; VWF, von Willebrand factor.*Interaction that has been shown to occur in endothelial cells.
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the WPB limiting membrane and the probable removal of
material. This remodeling process is especially poorly
understood, and is currently represented only by EM
images of clathrin-coated buds on WPBs [8]. Neither spe-
cific cargoes nor the adaptor(s) involved have yet been
identified.
Secretion of VWF can take place by one of three
pathways: regulated, secretagogue-stimulated release of
VWF from WPBs; basal, secretagogue-independent
release of VWF from WPBs; or constitutive, secreta-
gogue-independent release of VWF from non-WPB
anterograde carriers. Initially, most secretion of VWF
from endothelial cells was thought to occur constitutively
[23]. However, a study of the multimeric state of endo-
thelial releasates by Tsai et al. [24] challenged this view,
and suggested that the majority of VWF was secreted by
the regulated secretory pathway. Most recently, Giblin
et al. [25] revisited the issue, and concluded that most of
the VWF released in the absence of secretagogue stimu-
lation is from WPBs, i.e. by basal secretion. Release of
VWF from constitutive carriers is therefore only appar-
ent when a component of the cytoplasmic machinery
such as AP-1 is ablated [15].
Post-scission, the immature WPB will either undergo
exocytosis basally or become anchored to F-actin, where
maturation continues before exocytosis [26]. Regulated
exocytosis will follow activation of the endothelial cells
by any of a large number of different secretagogues [27].
Exocytosis of WPB; mechanisms and machinery
Bringing an organelle to the plasma membrane for subse-
quent exocytosis is a multistep process, involving sequen-
tial stages that may include tethering, docking, priming,
and fusion [28]. In the case of WPB exocytosis, much is
not yet understood, including which of the above stages
may exist in the endothelial regulated secretory system
(Fig. 1).
Peripheral anchoring of WPBs to allow maturation
There is an absolute physiologic requirement for the
release of high molecular weight VWF multimers, as an
absence of just the very highest molecular weight forms
results in a bleeding diathesis (such as observed in
type 2A and type 2B von Willebrand disease) [29]. Given
that multimerization continues in WPBs after their scis-
sion from the TGN [9], this places particular importance
on this maturation step. This pre-exocytic stage is sup-
ported by Rab27A, a GTPase that is often associated
with lysosome-related regulated secretory organelles,
where it generally acts via its effectors to link organelles
to cortical actin filaments [30–33]. Rab27A was the first
WPB Rab to be identified, and Hannah et al. showed
that this Rab is not only recruited to WPBs in endothelial
cells, but also recruited to the pseudo-WPBs induced by
the heterologous expression of VWF in HEK293 cells.
These data show that Rab27A is recruited by a remark-
able content-driven, maturation-dependent mechanism
that is independent of cell type [34].
Subsequent work by Nightingale et al., using small
interfering RNA (siRNA)-mediated suppression of
Rab27A, revealed a number of related phenotypes.
First, depletion in human umbilical vein endothelial cells
(HUVECs) over a period of 6 days led to a redistribu-
tion of WPBs from a peripheral to a more perinuclear
localization. Second, this redistribution was accompa-
nied by increases in both basal, phorbol-12-myristate-13-
acetate (PMA)-evoked and histamine-evoked release.
Third, the VWF released from Rab27a-deficient cells is
less highly multimerized than that released from con-
trols, and gives rise to shorter VWF strings under flow
(incidentally demonstrating a link between degree of
multimerization and length of strings). These data sug-
gest that Rab27A acts to modulate the maturation state
of the released VWF in a manner that is dependent on
the intracellular distribution of WPBs; Rab27A thus
acts to anchor the WPBs to filamentous actin and inhi-
bit release to allow appropriate maturation, and full
multimerization to be completed. Secretagogue activa-
tion of the endothelial cell leads to release from anchor-
age, and fusion with the plasma membrane, leading to
secretion of the VWF [26].
All Rabs act through their effectors. Rab27A has 11
reported effectors, and Nightingale et al. found that sev-
eral of these were expressed in HUVECs, including myo-
sin and Rab27a-interacting protein (MyRIP), granuphilin
(Slp4a), Slp3, Noc2, Munc13-4, and Slp2a. They analyzed
the role of MyRIP, the most highly expressed of these, in
HUVECs. They found that Rab27A is recruited to
maturing WPBs, that this is followed by recruitment of
MyRIP, and that the acquisition of MyRIP by WPBs is
associated with peripheral distribution. The effects of siR-
NA suppression of MyRIP were similar to those of siR-
NA suppression of Rab27a, i.e. an increase in PMA-
evoked release of VWF, and a marked loss of the more
peripherally located WPBs. The secretion phenotype
found following suppression of MyRIP was less marked
than that seen following suppression of Rab27a, suggest-
ing potential additional roles for other effector proteins
[26]. Subsequently, Pulido et al. [19] showed that the
actin-binding protein MyoVa binds to MyRIP, complet-
ing a tripartite link between F-actin and the WPB.
Modes of exocytic fusion events
The secretion of material from granules can occur in sev-
eral modes. In addition to simple exocytosis of secretory
carriers fusing individually with the plasma membrane, in
some cells compound multivesicular or cumulative fusion
has been reported [35]. The former refers to granules fus-
ing with each other and then the plasma membrane, as in
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mast cells, where massive simultaneous release of all
secretory cargoes occurs [36]. The latter is a variant
where, after initial fusion of a granule with the plasma
membrane, subsequent granules fuse to that same struc-
ture. Eosinophils use a mixture of both of these strategies
to produce a massive, but focused, release of cytotoxic
proteins [37].
Valentijn et al. used EM analyses of activated endothe-
lial cells to suggest that WPBs exocytose via multivesicu-
lar compound exocytosis. They describe a phenomenon
whereby there is intracellular homotypic fusion of WPBs
into a super-sized collapsed granule to produce a struc-
ture that they name a ‘secretory pod’ [38]. This then ini-
tially fuses to the plasma membrane via a thin tubule,
similar to that seen by Rosenthal et al. in one cryo-EM
image, where it is apparently connecting a single cigar-
shaped WPB to the plasma membrane [39]. The initial
description by Valentijn et al. leaves many unanswered
questions, such as whether this is an obligatory route for
release of VWF – which is improbable, as the movies
from other laboratories [40–44] overwhelmingly show
exocytosis from single granules – or a minor variant. If
the latter is the case, then under what physiologic circum-
stances might it be employed by endothelial cells, and
what would be the advantages and disadvantages for the
cell? Finally, the data currently available do not yet rule
out cumulative compound exocytosis as an additional
possibility for WPB fusion.
Even the fusion event itself is not simple in the case of
WPBs. A detailed analysis of WPB fusion by Babich
et al. [41] revealed that this is not an all or nothing event.
In common with other secretory systems [45], the exocytic
pore can remain open after initial fusion until all of the
content has been released (full fusion), or can reclose (kiss
and run). Babich found a stimulatory regime for endothe-
lial cells that drives WPBs into a state that they colorfully
describe as a long lingering kiss. This allows for the effec-
tive release of smaller molecules, such as cytokines, but
retains the VWF within the collapsed WPB (after fusion,
the open pore leads to a rise in intra-WPB pH, leading,
in turn, to a loss of the VWF tubular structures, and thus
a loss of the cigar shape). This could allow endothelial
cells to tune their response to different secretagogues,
allowing a release of content that has a lower ratio of
VWF to cytokines and is thus less thrombotic and more
inflammatory.
Thus, the overall mechanism by which WPBs engage
with the plasma membrane to release their content is still
not completely understood; and what of the molecular
machinery that will drive this multistep process?
Tethering, docking and fusion machinery
The first cellular machinery to be identified as likely to be
involved in tethering WPBs at the plasma membrane was
identified by Voorberg et al. They found the small
GTPase RalA to be associated with WPBs [46], and went
on to show that expression of mutants of this protein
could strongly affect the evoked release of VWF. RalA is
a component of the exocyst, a tethering complex that also
interacts with soluble N-ethylmaleimide-sensitive factor
(NSF) attachment protein receptors (SNAREs) and their
regulators, including Rabs – see below. In addition to
tethering factors, Munc13-4 [47] and Munc18c [48], a
member of another family of SNARE modulators – the
SM proteins – have been identified as playing a role in
VWF secretion. SM proteins can regulate exocytosis by
binding to syntaxins (plasma membrane Q-SNAREs) and
modulating their conformation [49]. It is noteworthy that
Munc13-4 was confirmed to be expressed in HUVECs by
Zografou et al. [47], and colocalizes with WPBs. It has
also been shown to act as an effector of Rab27A (see
below). Yet another regulator of fusion involved in endo-
thelial exocytosis is Slp4a/granuphilin. Granuphilin is a
positive regulator of VWF secretion [50] and is a third
effector of Rab27A. It has been shown to act in docking
insulin granules to the plasma membrane in pancreatic b-
cells [51].
It is noteworthy that Rab27A and (particularly) granu-
philin are located at the very tip of the WPB that then fuses
with the plasma membrane (Nightingale and Cutler,
unpublished data). Rab27a is thus involved in more than
one stage of secretion, acting in different ways on each
occasion. How this change in function is managed is not
clear, although it must be centered on a change in effector.
Finally, the annexin A2–S100A10 complex has also
been shown to be needed for VWF secretion [52], but,
although it probably acts late in exocytosis at the plasma
membrane (possibly playing a regulatory role via its lipid-
binding and calcium-binding properties), just how it fits
into the process is not yet clear.
In attempting to unravel some of the complexities of
VWF secretion, Bierings et al. [50] carried out a compara-
tive analysis of both MyRIP and Slp4a. Slp4a can bind
plasma membrane-associated syntaxins [53,54] and
Munc18 [55–57], to link secretory granules to exocytic
SNAREs. It can also interact with Rabs other than
Rab27A, including Rab3A, Rab3B, Rab3C, and Rab3D
[58], and with MyoVa [59]. They found that MyRIP is a
negative regulator of VWF release in response to hista-
mine, in agreement with Nightingale et al., whereas Slp4a
acts as a positive regulator. This suggests that Slp4a inter-
acts with the exocytic machinery in the endothelial sys-
tem, again suggesting that there may be a population of
WPBs within HUVECs that are somehow docked at the
plasma membrane, or a role for a docking phase distinct
from the earlier anchoring phase. They conclude by pro-
posing that the balance of the two effectors recruited by
Rab27A will determine the probability of release of
WPBs [50].
The other Rab that is associated with WPBs is Rab3D
[52], and overexpression of mutants of this Rab has been
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reported to interfere with WPB formation and thereby
affect VWF secretion. However, Bierings et al. reported
that siRNA suppression of Rab3B or Rab3D interferes
with the recruitment of Slp4a but not with VWF secre-
tion; they found that exocytosis was affected only via
suppression of Rab27A. They did, however, confirm the
inhibitory effect of overexpression of Rab3D on secretion,
but found that this was indirect, and resulted from com-
petition of Rab27a for Slp4a effector proteins. They also
mention that Rab3B is the major isoform, with 95% of
expression, with Rab3D representing only 5% of
expressed Rab3 [50].
A set of data from Zografou et al. [47] significantly
complicates this picture. They carried out an overexpres-
sion screen of green fluorescent protein-tagged Rabs in
HUVECs, and found not only those reported by others –
Rab27A, Rab3B, and Rab3D – but also that the other
isoforms of Rab3, the other isoform of Rab27, as well as
Rab15, Rab33A, and Rab37, are targeted to WPBs. Of
these, Rab15 is the most unexpected, as an established
endocytic Rab. They depleted these Rabs by siRNA abla-
tion, and, by examining their role in secretion with a mix-
ture of ATP, vascular endothelial growth factor and basic
fibroblast growth factor as secretagogues, determined that
Rab3A, Rab3D, Rab27A and Rab15 are all needed for
secretion of VWF. Thus, while confirming the role of
Rab27A, they introduce a further three Rabs as being
required for exocytosis of WPBs. Rab3A was not found
to be expressed in HUVECs by Bierings et al., although
overexpression of this isoform showed it to localize to
WPBs in HUVECs. Both Knop and Bierings have dem-
onstrated that Rab3D is expressed in HUVECs and colo-
calizes with WPBs, but Bierings and Zografou disagree as
to whether it functions in exocytosis. In overexpression
studies, Rab3D was reported by Knop to affect the for-
mation of WPBs, by Bierings, using siRNA ablation, not
to affect the release of VWF, but by Zografou, again
using siRNA, to indeed affect the release of VWF. Thus
far, only Zografou et al. have reported a WPB localiza-
tion and function for Rab15.
Zografou also introduce analyses of the third Rab
effector to be studied in endothelial cells, Munc13-4 [47].
This protein, identified as a Rab27A effector that is
widely expressed in hemopoietic cells, is involved in the
priming of secretory granules, and promotes SNARE
complex formation [60]. Zografou et al. have found that
siRNA suppression of Munc13-4 reduces VWF secretion
and that, in addition to Rab27A, it interacts with Rab15.
They suggest that both Rabs act through this effector.
The role of an endocytic Rab (15) in exocytosis of WPBs
is difficult to interpret, but they suggest that it might
relate to the well-known delivery from endosomes of
WPB components, including CD63, the essential cofactor
of the WPB integral membrane protein P-selectin [61].
The studies by Bierings et al. and Zografou et al. found
a fall in the evoked release of VWF from Rab27A-
depleted cells; this is in contrast to the increase in release
demonstrated by Nightingale et al. Bierings et al. did,
however, confirm the negative regulatory role for the
Rab27a effector MyRIP suggested by Nightingale et al.
The difference in Rab27a depletion phenotype between
these two studies may reflect the different timescales of
their depletion experiments. If MyRIP and Rab27a do, as
hypothesized, provide a brake that allows maturation,
then longer-term depletion of Rab27A could result in an
entirely immature population of WPBs that are hyperres-
posive to secretagogue. Such an effect may be masked by
the other Rab27a effectors (Munc13-4 and Slp4a) in a
shorter experimental timescale.
Many of these proteins are probably operating on the
fusion machinery at the heart of exocytosis. The core
components of this fusion machinery are the SNARE
complexes, and for WPBs in endothelial cells these are
currently thought to be Vamp3, syntaxin 4, and SNAP23.
Lowenstein et al. [62] first suggested that Vamp3 on the
WPBs, and syntaxin 4 and SNAP23 on the plasma mem-
brane, were the SNARE complexes involved in WPB
fusion in experiments exploring how nitric oxide inhibits
vascular inflammation. After identifying NSF nitrosyla-
tion as the cause of the reduced inflammatory response,
they showed that antibodies against VAMP3 and Syt4
reduced the secretion of VWF from permeabilized human
aortic endothelial cells. Fu et al. [48] followed this by
showing that Syt4 was phosphorylated following endothe-
lial activation, and that its suppression by siRNA reduced
P-selectin exposure at the plasma membrane of activated
human lung microvascular endothelial cells. More
recently, Pulido et al. [63] performed a focused study of
WPB SNAREs in HUVECs, using combinations of per-
meabilized cells, siRNA ablation, and mutant proteins,
and confirmed that Vamp3, Syt4 and SNAP23 are likely
to be the core components of the WPB exocytic SNARE
complex.
To further complicate analyses of VWF secretion with
another layer of regulatory machinery, Nightingale et al.
[44,64] have described yet another way in which endothe-
lial cells can modulate the secretory consequences of
fusion. They described a novel postfusion role for actin in
VWF secretion. In addition to F-actin providing a struc-
ture for Rab27A to anchor WPBs via MyRIP and My-
oVa (see above), thus facilitating their maturation, they
found that an actomyosin IIB ring or cup is rapidly
formed around the plasma membrane-distal end of the
WPB immediately after fusion, and that this is needed for
extrusion of VWF: Poisoning of myosin IIB allows the
fused WPB to remain fused at the plasma membrane with
its cargo of VWF sitting in the collapsed WPB.
Thus, mechanisms involved in tethering, docking, prim-
ing, fusion (albeit only as defined in other secretory sys-
tems) and cargo extrusion have been found, but these are
only the bare bones of the exocytic process for WPB;
how they interact, what other components are involved
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and how they interact with the signaling pathways arising
on endothelial activation (and which have been reviewed
elsewhere) are still to be established.
One interesting new way of finding new components
may be through genome-wide association studies of VWF
and FVIII plasma levels and the associated risk of throm-
bosis [65]. Recent analyses of this type have found that
not only a syntaxin-binding protein (syntaxin-binding
protein 5) but also another syntaxin (syntaxin 2) have
been associated with increases in the levels of plasma
VWF and thrombosis [66–69]. The former protein is also
known as tomosyn, and is thought to regulate exocytosis
in other systems [70,71], whereas the latter has not previ-
ously been thought to be involved in VWF secretion.
Whether components identified by broad genetic analyses
are directly involved in WPB exocytosis, or act more indi-
rectly, remains to be established. Indeed, whether a great
deal of further machinery is still to be found is unclear;
certainly, there are significant issues still unresolved.
One puzzle relates to the docking of WPBs in endothe-
lial cells. A conventional view of granule docking, mainly
derived from neuroendocrine granules, has developed
from a morphologic definition arising from the secretory
organelles being closely apposed to the plasma mem-
brane. In endothelial cells, this has not yet been estab-
lished, although the machinery for doing so may be
emerging, but ‘docking’ by anchoring to filamentous actin
has been described. Whether both of these processes
occur separately in the endothelium, and, if so, how they
relate to each other is as yet unclear.
Conclusions
As should be clear from the above discussion, the identity
and functioning of Rabs associated with WPBs has been
a particularly active area of WPB research in the last few
years. This is because the small GTPases of the Rab fam-
ily act as master controllers of cellular membrane biology,
acting from organelle formation to exocytosis [72], Thus
far, Rabs identified as localizing to WPBs have only been
found on mature organelles. These include Rab3A,
Rab3B, Rab3C, Rab3D, Rab15, Rab27A, Rab27B,
Rab33A, and Rab37 [26,34,47,50,52]. The other Rabs
playing a role in VWF secretion are Rab10 and Rab8A,
which do not colocalize with WPBs but are associated
with the Golgi in HUVECs, and were found to interact
genetically with AP-1 (in a Caenorhabditis elegans screen)
and therefore possibly play a role in WPB biogenesis [73].
It is interesting that Rab8 has also been shown to interact
with the exocyst, and is probably involved in exocytosis
(see above), but is also thought to act in trafficking from
the Golgi [74].
In addition, each Rab will act through its effectors,
recruited by the Rab in its GTP-loaded state, when it is
switched on. The list of investigated endothelial WPB-
associated effectors (MyRIP, Slp4a, and Munc13-4) is
therefore currently shorter than the numbers of Rabs,
and some are known to interact with more than one of
the identified Rabs. This very large collection of Rabs is
consistent with their playing more than one role in WPB
functioning and VWF secretion, which will make discov-
ering precisely what might be their individual contribu-
tion, within a system of cooperation and competition,
extremely challenging. As discussed above, the picture is
further complicated by discrepancies between the pub-
lished reports.
A necessarily speculative summary of the current Rab-
related data would place Rab27 at the center of the con-
trol of exocytosis. It acts to anchor WPBs to actin via
MyRIP and MyoVa to support maturation, and then
switches to other effectors to allow it to bind to the
SNARE complex at the plasma membrane via granuphi-
lin and/or Munc13-4 to support fusion. Rab3D and
Rab3B might assist in recruiting some effectors, and
Rab15 could play a role in reinforcing the later SNARE-
binding stages of exocytosis. In other organellar systems
where multiple Rabs are present on a single organelle, a
Rab cascade can occur, whereby an upstream Rab
recruits the GDP/GTP exchange factor for the down-
stream Rab; this cascade can be further bolstered by the
downstream Rab subsequently recruiting a GTPase-acti-
vating protein specific for the upstream Rab. This is best
understood for Rab5 and Rab7 [75–77], and has been
hypothesized for Rab9 with Rab32 and Rab38 [78]. Such
a cascade has been suggested for other regulated storage
organelles that recruit both Rab27a and Rab3, such as
the acrosome [79]. Where active Rab27a increases the
likelihood of the presence of GTP-loaded Rab3, such a
situation could allow the handover of common effector
proteins. This does not, however, fit with the release of
WPBs; first, Rab3 can be found on Rab27a-deficient
WPBs, and second, removal of Rab27a and of Rab3 give
different secretory phenotypes. As yet, it is unclear what
could allow the balance of Rab27a effectors to shift from
MyRIP to Slp4a or Munc13-4 (i.e. from negative to posi-
tive effector). Perhaps, as suggested by Bierings et al., it
could result from the fact that Slp4a can bind GDP-
bound Rab, or from the increased affinity of Slp4a as
compared to that of MyRIP for Rab27a. This will pro-
vide an interesting and active area of research.
In general, much of the data now available suggest that
differences between experimental conditions may affect
the outcome of experiments, and that interpretation of
such an overall picture will require caution and further
extensive analyses. Altogether, the state of play with
respect to VWF secretion is that many of the stages are
being defined, both morphologically and by molecular
mechanistic analyses, but that such studies are early
stages in the task of producing a fully integrated and
detailed picture of how such a complex process acts in an
integrated and physiologically responsive way. What can
be said at this early stage is that the secretion of VWF is
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likely to occur via one of the most highly regulated secre-
tory systems, and that the interest in this is unlikely to
disappear anytime soon.
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